Obese patients often require higher doses of anticoagulants due to increased volume of distribution. Adjusting dosages avoids subtherapeutic effects.

For obese individuals, anticoagulant dosing needs careful calibration to manage the altered pharmacokinetics and pharmacodynamics linked to greater body mass.

In obese patients, precisely tailored anticoagulant doses prevent both underdosing, which risks clot formation, and overdosing, which can cause bleeding.

Anticoagulant therapy in obese patients must account for altered drug metabolism and clearance, necessitating potentially higher, carefully monitored doses.